DKK169.10
17.43% yesterday
Copenhagen, Nov 15, 05:00 pm CET
ISIN
DK0015998017
Symbol
BAVA
Sector
Industry

Bavarian Nordic Stock price

DKK169.10
-43.90 20.61% 1M
-1.90 1.11% 6M
-8.35 4.71% YTD
+17.45 11.51% 1Y
-139.30 45.17% 3Y
+5.60 3.43% 5Y
-8.40 4.73% 10Y
Copenhagen, Closing price Fri, Nov 15 2024
-35.70 17.43%
ISIN
DK0015998017
Symbol
BAVA
Sector
Industry

Key metrics

Market capitalization DKK13.30b
Enterprise Value DKK11.19b
P/E (TTM) P/E ratio 18.27
EV/FCF (TTM) EV/FCF 5.74
EV/Sales (TTM) EV/Sales 1.84
P/S ratio (TTM) P/S ratio 2.19
P/B ratio (TTM) P/B ratio 1.27
Revenue growth (TTM) Revenue growth 9.82%
Revenue (TTM) Revenue DKK6.08b
EBIT (operating result TTM) EBIT DKK717.06m
Free Cash Flow (TTM) Free Cash Flow DKK1.95b
Cash position DKK2.24b
EPS (TTM) EPS DKK9.26
P/E forward 17.17
P/S forward 2.97
EV/Sales forward 2.58
Show more

Is Bavarian Nordic a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Bavarian Nordic Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Bavarian Nordic forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a Bavarian Nordic forecast:

Buy
80%
Hold
20%

Financial data from Bavarian Nordic

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
6,076 6,076
10% 10%
100%
- Direct Costs 2,621 2,621
43% 43%
43%
3,455 3,455
6% 6%
57%
- Selling and Administrative Expenses 314 314
9% 9%
5%
- Research and Development Expense 1,821 1,821
7% 7%
30%
1,320 1,320
23% 23%
22%
- Depreciation and Amortization 603 603
32% 32%
10%
EBIT (Operating Income) EBIT 717 717
43% 43%
12%
Net Profit 707 707
34% 34%
12%

In millions DKK.

Don't miss a Thing! We will send you all news about Bavarian Nordic directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. Its products include IMVAMUNE for Ebola, HPV, HBV, and HIV diseases. The company was founded in 1994 and is headquartered in Kvistgaard, Denmark.

Head office Denmark
CEO Paul Chaplin
Employees 1,379
Founded 1992
Website www.bavarian-nordic.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today